Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men
Authors' conclusion
We demonstrate that chronic subcutaneous kisspeptin administration sustains gonadotropin and testosterone secretion in healthy men for 12 days.
Study context
- Population
- Healthy men12 men served as controls
- Participants
- 15 participants
- Comparison
- SC kisspeptin-10 vs vehicle
Methodological detailssingle-blinded, placebo-controlled
- Single-blinded
- Placebo-controlled
Primary result
As reported in the abstract
Mean LH increase with daily 8 h SC infusions (study 3) · 12 days
| Group | Value | Day 1 | Day 12 |
|---|---|---|---|
| Vehicle | mean −0.16 (unspecified 0.19) | ||
| Kisspeptin-10 | mean +1.68 (unspecified 0.25) | +1.68 ± 0.25 | +1.14 ± 0.33 |
Value
Vehiclemean −0.16 (unspecified 0.19)
Kisspeptin-10mean +1.68 (unspecified 0.25)
Day 1
Vehicle— not stated in the abstract
Kisspeptin-10+1.68 ± 0.25
Day 12
Vehicle— not stated in the abstract
Kisspeptin-10+1.14 ± 0.33
- Kisspeptin-10 vs Vehicle: P = 0.003 vs vehicle
Further findings
| Outcome | P value |
|---|---|
| Acute dose-response: LH, FSH and testosterone (study 1) · 8 h | P < 0.0001 |
Acute dose-response: Luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone (study 1) · 8 h
- Acute SC kisspeptin-10 infusions dose-dependently increased LH, FSH and testosterone vs vehicle
Continuous infusion (study 2) · 5 days
- Testosterone remained elevated; gonadotropin concentrations similar to vehicle
Response to kisspeptin-10 bolus (1 nmol/kg) after 12 days
- Gonadotropin rises still detected, indicating kisspeptin receptor remained functional
Original publication
Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. Published 4 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →